

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

**POLL RESULTS OF
THE ANNUAL GENERAL MEETING
APPOINTMENT OF NON-EXECUTIVE DIRECTOR
AND
AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The board (the “**Board**”) of directors of Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on May 15, 2026, the proposed resolutions as set out in the notice of the AGM (“**Notice of the AGM**”) were duly passed by the Shareholders of the Company by way of poll. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated April 24, 2026 (the “**Circular**”).

POLL RESULTS OF THE AGM

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)		
		For	Against	Abstain
1.	To consider and approve the work report of the Board of Directors of the Company (the “ Board ”) for the year 2025.	126,551,966 (99.9987%)	0 (0.0000%)	1,600 (0.0013%)
2.	To consider and approve the final financial report of the Company for the year 2025.	126,551,966 (99.9987%)	0 (0.0000%)	1,600 (0.0013%)
3.	To consider and approve the annual report of the Company for the year 2025.	126,551,966 (99.9987%)	0 (0.0000%)	1,600 (0.0013%)
4.	To consider and approve the profit distribution plan of the Company for the year 2025.	126,551,966 (99.9987%)	0 (0.0000%)	1,600 (0.0013%)

Ordinary Resolutions		Number of Votes (Approximate %)		
		For	Against	Abstain
5.	To consider and approve the appointment of Dr. Wu Fenglan (吳鳳嵐) as a non-executive Director of the Company.	125,046,010 (98.8088%)	1,505,956 (1.1900%)	1,600 (0.0013%)
6.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for the year 2026 and to authorise the Board to determine its remuneration.	126,551,966 (99.9987%)	0 (0.0000%)	1,600 (0.0013%)
7.	To consider and approve the directors remuneration plan for the year 2026.	126,521,545 (99.9747%)	30,421 (0.0240%)	1,600 (0.0013%)
Special Resolutions		Number of Votes (Approximate %)		
		For	Against	Abstain
8.	To consider and approve granting of a general mandate to the Board to exercise the right to allot, issue and deal with additional shares (including the sale or transfer of treasury shares) of the Company.	122,017,044 (96.4153%)	4,534,259 (3.5829%)	2,263 (0.0018%)
9.	To consider and approve the proposed grant of general mandate to the Board to repurchase H shares of the Company.	126,551,303 (99.9982%)	0 (0.0000%)	2,263 (0.0018%)
10.	To consider and approve the amendments to the Articles of Association.	126,551,966 (99.9987%)	0 (0.0000%)	1,600 (0.0013%)

Notes:

- (1) For details, please refer to the Circular.

As more than half of the votes were cast in favour of the above resolutions numbered 1 to 7 proposed at the AGM, each of the aforesaid resolutions was duly passed as an ordinary resolution.

As majority of more than two-thirds of the votes were cast in favor of resolutions numbered 8 to 10 at the AGM, each of the aforesaid resolutions were duly passed as a special resolution.

- (2) As at the date of the AGM, the total number of issued Shares of the Company was 198,891,800 Shares, including 45,613,109 Unlisted Shares and 153,278,691 H Shares; among which 1,796,400 unvested H Shares were held by the trustee under the H Share Award Scheme adopted by the Company on December 17, 2025, and such trustee was required to abstain from voting on all resolutions proposed at the AGM and has so abstained. Accordingly, as at the date of the AGM, the total number of Shares entitling the holders to attend the AGM and to vote for or against the proposed resolutions was 197,095,400 Shares (comprising 45,613,109 Unlisted Shares and 151,482,291 H Shares).

There were no treasury Shares (including any treasury share deposited with CCASS) or repurchased share pending cancellation held by the Company.

The Shareholders and their proxies present at the AGM hold a total of 126,553,566 Shares carrying voting rights of the Company, representing approximately 63.63% of the number of total issued Shares of the Company.

No Shares were actually voted but excluded from calculating the poll results.

- (3) Save as disclosed above, as at the date of the AGM, (i) none of the Shareholders was required to abstain from voting on any resolution proposed at the AGM pursuant to the Listing Rules; (ii) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of any resolution proposed at the AGM as set out in Rule 13.40 of the Listing Rules; and (iii) none of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any resolutions proposed at the AGM.
- (4) The Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.
- (5) The executive directors, Dr. Kang Xiaoqiang, Dr. Lai Shoupeng and Mr. Zuo Honggang, non-executive directors, Mr. Zhang Yincheng and Dr. Chen Renhai, and independent non-executive directors, Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu attended the AGM either in person or by electronic means.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Wu Fenglan (吳鳳嵐) (“**Dr. Wu**”) was appointed as a non-executive Director of the Company with effect from May 15, 2026 and ending on the expiry of the term of the first session of the Board, and Dr. Wu is eligible for re-election at the general meeting upon the expiry of her term of office in accordance with the articles of association of the Company.

The biographical details of Dr. Wu are set out in the Circular. As of the date of this announcement, there have been no changes to the biographical details of Dr. Wu.

The Company will enter into a Director's service contract with Dr. Wu as soon as possible. Dr. Wu will not receive Director's emolument for her position as the non-executive Director of the Company.

As of the date of this announcement, save as disclosed above, Dr. Wu had confirmed that: (i) she did not have any relationship with any other Directors, senior management, substantial or controlling Shareholders, or single largest group of Shareholders of the Company (as respectively defined in the Listing Rules); (ii) she did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) she did not hold any other positions within the Group; and (iv) she did not hold any directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above, to the best knowledge, information and belief of the Directors having made all reasonable enquiries, there is no other information relating to the appointment of Dr. Wu that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to her appointment that need to be brought to the attention of the Shareholders.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

As a special resolution in relation to the proposed amendments to the Articles of Association has been duly approved by the Shareholders at the AGM, the amended Articles of Association shall take effect on May 15, 2026. The amended Articles of Association will be published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.leadsbiolabs.com), respectively.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, May 15, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.